Mylan Sues FDA Alleging Inaction And Failure To Share Clarity On Ranbaxy's Atorvastatin Filings
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Two months after settling a patent litigation with Pfizer Inc. for cholesterol-reducing agent Lipitor (atorvastatin), generic drugs major Mylan Pharmaceuticals Inc. has charged that U.S. FDA's failure to decide and disclose critical information related to Ranbaxy Laboratories' Ltd. abbreviated new drug application for atorvastatin is "unlawful, arbitrary and capricious.
You may also be interested in...
Talk Of $1 Billion Fine On Ranbaxy By U.S. FDA Dents Stock; Analysts Divided Over Exact Penalty
MUMBAI - Shares of Ranbaxy Laboratories Ltd., listed on the Indian stock exchanges, plunged 6% May 5 to 426 Indian Rupees ($9.48) per share, reacting sharply to a Fortune magazine report that claimed the company may be fined over $1 billion as part of a protracted negotiation and settlement process with U.S. FDA
Talk Of $1 Billion Fine On Ranbaxy By U.S. FDA Dents Stock; Analysts Divided Over Exact Penalty
MUMBAI - Shares of Ranbaxy Laboratories Ltd., listed on the Indian stock exchanges, plunged 6% May 5 to 426 Indian Rupees ($9.48) per share, reacting sharply to a Fortune magazine report that claimed the company may be fined over $1 billion as part of a protracted negotiation and settlement process with U.S. FDA
Lipitor Generics: Ranbaxy Still In The Driver's Seat As Court Dismisses Mylan Lawsuit Against U.S. FDA
Two unresolved factual matters stand in the way of Mylan Pharmaceuticals Inc.' s bid to sue U.S. FDA over generic marketing exclusivity for Pfizer's Lipitor, a U.S. federal judge ruled May 2